SEC Form 4 · accession 0001209191-16-088105
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
L Daniel Browne
Officer — CEO and President · Director
Period of report
Dec 30, 2015
Accepted (ET)
Jan 4, 2016 · 9:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 30, 2015 | M | 12,045 | $2.55 | A | 218,415 | D | |
| Common StockF2 | Dec 31, 2015 | J | 262 | $27.00 | A | 218,677 | D | |
| Common StockF3 | holding | — | — | — | 409 | I | See footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F4 | $2.55 | Dec 30, 2015 | M | 12,045 | D | — | Jul 20, 2020 | Common Stock | 12,045 | 24,621 | D |
Explanation of responses
- F1Mr. Browne performed a cash exercise to acquire these shares.
- F2These shares were purchased by Mr. Browne under Revance's 2014 Employee Stock Purchase Plan on December 31, 2015 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- F3These shares are held by the Dan and Brenda Browne Living Trust. Mr. Browne is a Trustee of the Dan and Brenda Browne Living Trust.
- F4The Option became fully vested as of January 1, 2014.